MSOS Rallies 15% as Trump Cannabis Pivot Sparks Rescheduling Optimism

The AdvisorShares Pure US Cannabis ETF (MSOS) surged 15% in early trading as cannabis investors react to emerging signals from the Trump administration regarding federal marijuana rescheduling. The rally marks the strongest single-day performance for the cannabis-focused fund since October 2023, pushing its year-to-date gains to 23% and reigniting institutional interest in a sector that has struggled with regulatory uncertainty.

Trump Administration Signals Policy Shift

The cannabis sector's momentum builds on growing speculation that the incoming Trump administration may accelerate federal rescheduling efforts initiated under the Biden presidency. Industry sources indicate that key Trump advisors have privately discussed maintaining continuity with the DEA's ongoing review process, which could move marijuana from Schedule I to Schedule III under the Controlled Substances Act. This potential policy continuity represents a dramatic shift from Trump's previous cannabis stance and reflects the evolving political calculus around marijuana reform.

The rescheduling process, currently under review by the Drug Enforcement Administration, would enable cannabis companies to claim standard business tax deductions under Section 280E of the tax code. For major operators like Curaleaf and Green Thumb Industries—MSOS's largest holdings—this change could improve EBITDA margins by 15-25% according to industry estimates. The tax relief alone could translate to hundreds of millions in additional cash flow across the sector.

MSOS Holdings Benefit from Regulatory Tailwinds

MSOS's portfolio composition positions the fund to capture upside from federal reform. The ETF holds $1.2 billion in assets across 24 cannabis companies, with 78% concentrated in multi-state operators that would benefit most from interstate commerce and banking access. Top holdings Curaleaf, Green Thumb Industries, and Trulieve Cannabis each gained between 12-18% following the Trump administration signals.

The fund's focus on profitable, cash-generating operators distinguishes it from broader cannabis investments. MSOS holdings generated combined revenues of $8.4 billion in the trailing twelve months, with 68% of portfolio companies reporting positive EBITDA. This operational foundation provides stability as regulatory catalysts emerge, contrasting sharply with the speculative cannabis bubble of 2021 when valuations disconnected from fundamentals.

Banking and Interstate Commerce Implications

Federal rescheduling would address two critical bottlenecks constraining cannabis sector growth: banking access and interstate commerce restrictions. Currently, most cannabis companies operate cash-intensive businesses due to federal banking prohibitions, creating operational inefficiencies and security risks. Rescheduling would enable traditional banking relationships, reducing operational costs and improving capital allocation.

Interstate commerce represents an even larger opportunity. MSOS holdings currently operate state-by-state silos, preventing economies of scale and forcing redundant infrastructure investments. Federal reform allowing interstate commerce could unlock $2-3 billion in cost synergies across major operators, according to cannabis industry analysts. Companies with strong brand portfolios and operational scale—core MSOS criteria—would capture disproportionate benefits from a unified national market.

Valuation Metrics Support Continued Upside

Despite recent gains, MSOS trades at attractive valuations relative to historical metrics and comparable consumer sectors. The fund's holdings trade at an average 2.1x enterprise value-to-sales multiple, compared to 4.2x for alcohol beverage companies and 3.8x for tobacco stocks. This valuation discount persists despite cannabis companies demonstrating faster revenue growth and similar profitability profiles.

The cannabis sector remains significantly undervalued relative to traditional vice categories, creating compelling risk-adjusted returns as regulatory uncertainty diminishes.

Institutional ownership of MSOS has increased 34% over the past six months, indicating growing confidence among professional investors. The fund's daily trading volume has averaged 2.1 million shares in December, up from 1.3 million in September, suggesting broader market participation beyond retail cannabis enthusiasts.

Market Outlook and Risk Considerations

The cannabis sector's regulatory catalyst timeline remains fluid despite recent optimism. The DEA's rescheduling review process could extend into late 2024 or early 2025, creating potential volatility as investors react to procedural developments. Additionally, rescheduling represents incremental reform rather than full federal legalization, maintaining certain regulatory constraints on cannabis businesses.

MSOS investors should monitor state-level developments alongside federal progress. Key markets including New York, New Jersey, and California continue expanding adult-use programs, providing fundamental growth drivers independent of federal action. The combination of state market maturation and potential federal reform creates multiple paths for sustained sector outperformance, supporting MSOS's position as the primary institutional vehicle for cannabis exposure.